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Abstract
Introduction Patients with haematological malignancy admitted
to intensive care have a high mortality. Adverse prognostic
factors include the number of organ failures, invasive mechanical
ventilation and previous bone marrow transplantation. Severity-
of-illness scores may underestimate the mortality of critically ill
patients with haematological malignancy. This study
investigates the relationship between admission characteristics
and outcome in patients with haematological malignancies
admitted to intensive care units (ICUs) in England, Wales and
Northern Ireland, and assesses the performance of three
severity-of-illness scores in this population.
Methods A secondary analysis of the Intensive Care National
Audit and Research Centre (ICNARC) Case Mix Programme
Database was conducted on admissions to 178 adult, general
ICUs in England, Wales and Northern Ireland between 1995
and 2007. Multivariate logistic regression analysis was used to
identify factors associated with hospital mortality. The Acute
Physiology and Chronic Health Evaluation (APACHE) II score,
Simplified Acute Physiology Score (SAPS) II and ICNARC
score were evaluated for discrimination (the ability to distinguish
survivors from nonsurvivors); and the APACHE II, SAPS II and
ICNARC mortality probabilities were evaluated for calibration
(the accuracy of the estimated probability of survival).
Results There were 7,689 eligible admissions. ICU mortality
was 43.1% (3,312 deaths) and acute hospital mortality was
59.2% (4,239 deaths). ICU and hospital mortality increased
with the number of organ failures on admission. Admission
factors associated with an increased risk of death were bone
marrow transplant, Hodgkin's lymphoma, severe sepsis, age,
length of hospital stay prior to intensive care admission,
tachycardia, low systolic blood pressure, tachypnoea, low
Glasgow Coma Score, sedation, PaO2:FiO2, acidaemia,
alkalaemia, oliguria, hyponatraemia, hypernatraemia, low
haematocrit, and uraemia. The ICNARC model had the best
discrimination of the three scores analysed, as assessed by the
area under the receiver operating characteristic curve of 0.78,
but all scores were poorly calibrated. APACHE II had the
highest accuracy at predicting hospital mortality, with a
standardised mortality ratio of 1.01. SAPS II and the ICNARC
score both underestimated hospital mortality.
Conclusions Increased hospital mortality is associated with the
length of hospital stay prior to ICU admission and with severe
sepsis, suggesting that, if appropriate, such patients should be
treated aggressively with early ICU admission. A low
haematocrit was associated with higher mortality and this
relationship requires further investigation. The severity-of-illness
scores assessed in this study had reasonable discriminative
power, but none showed good calibration.
APACHE II: Acute Physiology and Chronic Health Evaluation II; AUROC: area under the receiver operating characteristic curve; CMPD: Case Mix 
Programme Database; GCS: Glasgow Coma Score; HSCT: haemopoeitic stem cell transplant; ICNARC: Intensive Care National Audit and Research 
Centre; ICU: intensive care unit; IMV: invasive mechanical ventilation; OR: odds ratio; SAPS II: Simplified Acute Physiology Score II; SMR: standard-
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Introduction
Patients with haematological malignancies can now expect a
greater chance of curative treatment and longer survival times
than ever before due to bone marrow (haemopoeitic stem cell)
transplantation and chemotherapy. Yet these potentially life-
saving treatments may also cause life-threatening complica-
tions [1-5]. Seven per cent of patients admitted to hospital
with haematological malignancy become critically ill [6], and
these patients have a higher mortality than the general inten-
sive care population [7-10].
Factors found to influence survival of patients admitted to the
intensive care unit (ICU) with a haematological malignancy
include the severity of the acute illness [11-13], invasive
mechanical ventilation (IMV) [5,14,15], and previous haemo-
poeitic stem cell transplant (HSCT) [11,12]. Neutropaenia
[12,16] and the nature and progress of the haematological
malignancy [9] may also predict a poor outcome. Probably due
to the small number of patients included, however, not all of
the factors mentioned above were predictive of adverse out-
come in subsequent studies.
Models that incorporate the effect of chronic health and spe-
cific diagnoses on mortality, such as the Acute Physiology and
Chronic Health Evaluation II (APACHE II) score and the Sim-
plified Acute Physiology Score II (SAPS II), are able to discrim-
inate survivors from nonsurvivors [12,16,17]. Despite this
ability, severity-of-illness scores significantly underestimate
actual mortality in this population of patients [6,8,11]. The
Intensive Care National Audit and Research Centre (ICNARC)
model was developed in 2007 using data from 216,626
admissions in the ICNARC database [18], and was shown to
be superior to existing risk prediction models. The ICNARC
model assesses acute physiology in addition to age, source of
admission, diagnostic category and cardiopulmonary resusci-
tation before admission. Unlike the APACHE II and SAPS II
models, the ICNARC model does not exclude patients with
specific diagnoses, like burns. The model, however, has never
been assessed for its accuracy in haematological malignancy
patients. The accuracy of a severity-of-illness score can be
assessed by the model's discrimination between survivors and
nonsurvivors (how well the model predicts the correct out-
come) and by assessing calibration (how well the model tracks
outcomes across the range of possible scores).
The present study examines the outcomes of haematological
malignancy patients admitted to general adult ICUs in Eng-
land, Wales and Northern Ireland, identified using a high-qual-
ity clinical database. We used multivariable logistic regression
analysis to identify factors on admission that are associated
with acute hospital mortality. We evaluated the discrimination
and calibration of the APACHE II, SAPS II and ICNARC mod-
els in these patients.
Materials and methods
Case Mix Programme Database
The Case Mix Programme is the national comparative audit of
adult, general critical care units (ICUs and combined intensive
care and high-dependency units) in England, Wales and
Northern Ireland, coordinated by the ICNARC. The Case Mix
Programme Database (CMPD) contains pooled case mix and
outcome data on consecutive admissions to units participating
in the Case Mix Programme, which have undergone extensive
local and central validation. The data are collected to precise
rules and definitions by trained data collectors. Details of the
data collection and validation have been reported previously
[19]. The CMPD has been independently assessed to be of
high quality [20]. Support for the collection and use of patient-
identifiable data without consent in the Case Mix Programme
has to be obtained under Section 251 of the NHS Act 2006
(approval number PIAG 2–10(f)/2005), and therefore ethical
approval was not required for the present study. Data were
extracted from the CMPD for 514,918 admissions from 178
ICUs, covering the period December 1995 to March 2007.
Selection of cases
Admissions in the CMPD with haematological malignancy can
be identified from the primary, secondary and ultimate primary
reason for admission fields, from either of two other conditions
relevant to the admission, and from the past medical history.
The reasons for admission and other conditions relevant to the
admission are coded using the ICNARC Coding Method [21],
a hierarchical method specifically designed for coding reasons
for admission to the ICU.
Admissions with any of the following ICNARC Coding Method
conditions as the primary, secondary or ultimate primary rea-
son for admission or other conditions relevant to the admission
were included in the analysis: bone marrow transplant, graft
versus host disease, acute lymphoblastic leukaemia, acute
myeloblastic leukaemia, chronic lymphocytic leukaemia,
chronic myelogenous leukaemia, Hodgkin's lymphoma, non-
Hodgkin's lymphoma or myeloma. All admissions that do not
satisfy these criteria but have any of the following conditions in
their past medical history were also included in the analysis:
acute myelogenous leukaemia or lymphocytic leukaemia or
multiple myeloma; chronic myelogenous leukaemia or chronic
lymphocytic leukaemia; or lymphoma. The conditions specified
above must have been present in the 6 months prior to admis-
sion to the unit in order to be included in the CMPD.
An algorithm was derived to divide these admissions into cat-
egories based on their reason for admission. This algorithm
was required because it is possible for each admission to have
more than one condition coded. The following hierarchy of rea-
son for admission was therefore used: acute lymphoblastic
leukaemia or acute myeloblastic leukaemia or myeloma;
chronic lymphocytic leukaemia or chronic myelogenousAvailable online http://ccforum.com/content/13/4/R137
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leukaemia; Hodgkin's lymphoma or non-Hodgkin's lymphoma;
and bone marrow transplant or graft versus host disease.
Each of the reasons for admission or each of the conditions
relevant to the admission was searched in turn for the condi-
tions in the order defined above and the admission was allo-
cated to the condition that was identified first. The primary
reason for admission was searched first, followed by the sec-
ondary reason, the ultimate reason and finally the other condi-
tions relevant to the patient's admission.
It is not possible to identify treatments received by the admit-
ted patient using the ICNARC Coding Method, so admissions
with the conditions bone marrow transplant or graft versus
host disease were considered to have received HSCT.
Data
Data were extracted on the case mix, on the outcome and on
the activity as defined below.
Case mix
Organ system failures were identified from physiological data
according to the definitions of Knaus and colleagues [22].
Severity of illness was measured by the APACHE II Acute
Physiology Score, the APACHE II score [22], the ICNARC
physiology score [18], the SAPS II score [23] and the number
of organ system failures. Both the APACHE II Acute Physiol-
ogy Score and the ICNARC physiology score encompass a
weighting for acute physiology (defined by derangement from
the normal range for 12 physiological variables in the first 24
hours following admission to the ICU). The APACHE II score
and the SAPS II additionally encompass a weighting for age
and for a past medical history of specified conditions.
Patients who were ventilated at any time during the first 24
hours in the ICU include both patients who were receiving
mechanical ventilation on admission to the ICU and those for
which ventilation was initiated at any time during the first 24
hours of their stay.
Patients were defined as having severe sepsis if they met at
least three of the four systemic inflammatory response syn-
drome criteria, if they had evidence of infection, and by the
presence of at least one organ dysfunction during the first 24
hours following admission to the ICU. Physiological definitions
of the systemic inflammatory response syndrome criteria and
organ dysfunctions were matched as closely as possible to
those used in the PROWESS trial, as has been reported pre-
viously [24].
Outcome
Survival data were extracted at discharge from the Case Mix
Programme unit and at ultimate discharge from the acute
hospital.
Readmissions
Readmissions to the unit within the same hospital stay were
identified from the postcode, date of birth and sex of the
patient, and were confirmed by the participating units.
Analyses
A statistical analysis plan was agreed a priori. The analyses
performed were as follows.
Descriptive statistics
The case mix, outcome and activity were described for all hae-
matological malignancy admissions.
Prognostic modelling in haematological malignancies
The effect of case mix factors on acute hospital mortality was
assessed by multivariable logistic regression modelling for the
admissions that were identified as having a haematological
malignancy. The past medical history as recorded in the
CMPD does not distinguish between individual haematologi-
cal diagnoses, but groups together the following diagnoses:
acute myelogenous leukaemia or lymphocytic leukaemia or
multiple myeloma; chronic lymphocytic leukaemia or chronic
myelogenous leukaemia; and Hodgkin's lymphoma or non-
Hodgkin's lymphoma. To assess the effect of specific haema-
tological diagnoses on outcome, therefore, only admissions
with a haematological diagnosis as the primary, secondary or
ultimate reason for admission were included in the regression
analysis of diagnosis on outcome.
For all physiology variables, all measurements were from the
first 24 hours following ICU admission. The variables entered
into the model, selected a priori, were as follows: age; sex;
haematological diagnosis on admission (only admissions with
a haematological diagnosis as the primary, secondary or ulti-
mate reason for admission were included in this analysis);
highest central temperature (or noncentral temperature + 1°C
if no central temperature was recorded); lowest systolic blood
pressure; highest heart rate; lowest respiratory rate;
PaO2:FiO2 (with additional weightings for patients who were
ventilated at any time during the first 24 hours of their admis-
sion to the unit); lowest arterial pH; serum sodium (most
extreme value from the normal range); serum potassium (most
extreme value from the normal range); serum urea (most
extreme value from the normal range); serum creatinine (most
extreme value from the normal range); urine output in the first
24 hours of admission to the unit (if the length of stay in the
unit was less than 24 hours the urine output during their stay
is scaled up to give the equivalent urine output in 24 hours);
haematocrit (most extreme value from the normal range; if
there were no haematocrit measurements available then three
times the recorded haemoglobin values were used instead);
lowest white blood cell count; lowest total Glasgow Coma
Score (GCS); IMV; severe sepsis; cardiopulmonary resuscita-
tion within 24 hours prior to admission; and acute hospital
length of stay before ICU admission in days.Critical Care    Vol 13 No 4    Hampshire et al.
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Continuous variables were divided into categories for model-
ling, except for age and hospital length of stay before ICU
admission, which were assumed to have a linear effect on the
log odds.
Evaluation of APACHE II, SAPS II and ICNARC models in 
haematological malignancy admissions
The SAPS II, the APACHE II score and the ICNARC physiol-
ogy score were evaluated for discrimination (the ability of the
model to distinguish survivors from nonsurvivors), and the
APACHE II mortality probability (using coefficients from the
model that has been calibrated using the CMPD [25]), the
ICNARC model mortality probability and the SAPS II mortality
probability were evaluated for discrimination and calibration
(the accuracy of the estimated probability of survival). The
APACHE II and ICNARC models are used to predict the prob-
ability of ultimate acute hospital mortality. The SAPS II model
is used to predict the probability of mortality within the same
hospital that houses the ICU where the admission occurred.
Discrimination was assessed by the area under the receiver
operating characteristic curve (AUROC) [26]. Calibration was
assessed by the standardised mortality ratio (SMR), the Hos-
mer–Lemeshow C statistic [27] and Cox's regression calibra-
tion [28].
The AUROC (also called the concordance statistic) measures
the probability that a randomly selected nonsurvivor has a
higher prediction than a randomly selected survivor. A value of
0.5 indicates no discrimination, and a value of 1 indicates per-
fect discrimination. Values higher than 0.8 are generally con-
sidered to demonstrate good discrimination, values between
0.6 and 0.8 are considered moderate, and values lower than
0.6 are considered poor.
The SMR can be used to compare the discrepancy between
observed and expected deaths between groups. The ratio is
calculated as the number of observed deaths divided by the
number of deaths predicted by the model.
The Hosmer–Lemeshow test divides the data into 10 groups
and compares the observed mortality in these groups with the
expected mortality predicted by the model. The C statistic is a
chi-squared statistic for testing the hypothesis of perfect cali-
bration (observed mortality = expected mortality). A significant
result indicates that calibration is not perfect [27].
Cox's regression calibration tests for a systematic lack of cali-
bration by performing a linear recalibration of the log odds. The
log odds are given by log(p/(1 - p)), where p is the mortality
probability. The following model is fitted:
If the model is perfectly calibrated then the slope will be 1 and
the intercept will be 0; that is, true log odds = predicted log
odds. This is tested with a likelihood ratio chi-squared test,
with a significant result indicating lack of calibration.
Readmissions within the same acute hospital stay were
excluded from all analyses of acute hospital mortality. Patients
who stayed less than 8 hours in the ICU were excluded from
the calculation of APACHE II scores and probabilities. In addi-
tion, patients transferred from another ICU and admissions fol-
lowing coronary artery bypass graft or for primary burns were
excluded from the calculation of APACHE II and SAPS II prob-
abilities. In addition, patients were excluded from the calcula-
tion of SAPS II probability if no respiratory rates were recorded
or no measurements from blood gases were taken. There are
no exclusions from the ICNARC model.
All analyses were performed using Stata 9.2 (Stata Corpora-
tion, College Station, TX, USA).
Results
Case mix
Patients with haematological malignancy accounted for 7,689
admissions (1.5% of all admissions) to ICUs between Decem-
ber 1995 and March 2007. Table 1 presents the characteris-
tics of the patients. Fifty-five per cent of patients were
ventilated during the first 24 hours of ICU admission, and
54.3% of patients had a physiological diagnosis of severe sep-
sis on admission.
Thrombocytopaenia was present in 4,745 (61.7%) patients,
with a median lowest recorded platelet count of 74 × 109/l.
Two thousand and twenty-nine (26.4%) patients were leuko-
paenic on admission.
Case-mix data for admissions by diagnostic category are pre-
sented in Table 2. The mean age differs according to the diag-
nostic category, with a greater mean age in the myeloma, the
chronic myelogenous or chronic lymphocytic leukaemia and
the non-Hodgkin's lymphoma categories, and lower mean
ages in the acute lymphocytic leukaemia and the bone marrow
transplant categories. Patients with chronic myelogenous or
chronic lymphocytic leukaemia had relatively higher median
admission leukocyte counts.
Outcome and activity
Overall 3,312 (43.1%) patients died in intensive care and
4,239 (59.2%) died during the hospital admission (Table 1).
The median length of stay on the ICU was 2.3 days, survivors
having a slightly longer median stay than nonsurvivors. Four
hundred and forty-nine (5.8%) patients were readmitted to the
ICU during the same hospital admission, and 166 (2.2%) were
transferred from another ICU. True log odds slope predicted log odds intercept =× +Available online http://ccforum.com/content/13/4/R137
Page 5 of 17
(page number not for citation purposes)
Table 1
Case mix for admissions with haematological malignancy
All admissions (n = 7,689)
Age, mean (SD) 57.5 (17.6)
Male, n (%) 4,638 (60.3)
APACHE II Acute Physiology Score, mean (SD) 17.1 (7.4)
APACHE II score, mean (SD) 24.4 (7.9)
ICNARC physiology score, mean (SD) 23.7 (11.4)
Number of organ system failures, mean (SD) 1.5 (1.2)
Ventilated at any time during the first 24 hours in the ICU, n (%) 4,244 (55.4)
Severe sepsis, n (%) 4,177 (54.3)
Physiology
Lowest platelet count (× 109/l), median (IQR) 74 (31 to 162)
Lowest white blood cell count (× 109/l), median (IQR) 6.7 (2.1 to 14.0)
Outcome
Mortality, n (%)
Unit 3,312 (43.1)
Hospitala 4,239 (59.2)
Activity
Unit length of stay (days), median (IQR)
Survivor 2.5 (1.0 to 5.9)
Nonsurvivor 2.2 (0.7 to 6.3)
All 2.3 (0.9 to 6.1)
Hospital length of stay (days)a, median (IQR)
Survivor 27 (14 to 50)
Nonsurvivor 14 (5 to 29)
All 19 (9 to 38)
Transferred in from another ICU, n (%) 166 (2.2)
Readmission within the same hospital stay, n (%) 449 (5.8)
Hospital mortality by number of organ system failures, mortality (95% CI)
0 organ failures 33.8 (31.4 to 36.2)
1 organ failure 50.3 (48.3 to 52.4)
2 organ failures 68.3 (66.1 to 70.4)
3 organ failures 83.9 (81.5 to 86.1)
4 organ failures 92.3 (89.3 to 94.6)
5 organ failures 98.8 (93.7 to 99.9)
APACHE, Acute Physiology And Chronic Health Evaluation; APS, acute physiology score; CI, confidence interval; ICNARC, Intensive Care 
National Audit & Research Centre; ICU: intensive care unit; IQR: interquartile range; SD: standard deviation. aExcluding readmissions within the 
same hospital stay.Critical Care    Vol 13 No 4    Hampshire et al.
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Table 2
Case mix for admissions with haematological malignancy by diagnostic category
AML (n = 622) ALL (n = 272) CMLL (n = 310)
Age, mean (SD) 49.8 (16.8) 33.5 (20.1) 61.7 (16.1)
Male, n (%) 331 (53.2) 143 (52.6) 205 (66.1)
APACHE II Acute Physiology 
Score, mean (SD)
20.1 (6.9) 18.6 (6.9) 17.2 (6.9)
APACHE II score, mean (SD) 26.3 (7.6) 23.8 (7.2) 24.9 (7.6)
ICNARC physiology score, mean 
(SD)
26.5 (11.1) 24.1 (11.2) 23.7 (11.4)
Number of organ system failures, 
mean (SD)
1.9 (1.2) 1.7 (1.1) 1.5 (1.1)
Mechanically ventilated at any time 
during first 24 hours in the ICU, n 
(%)
329 (53.1) 129 (47.6) 165 (53.4)
Severe sepsis, n (%) 284 (45.7) 121 (44.5) 137 (44.2)
Physiology
Lowest platelet count (× 109/l), 
median (IQR)
26 (13 to 51) 34 (19 to 62) 61 (34 to 121)
Lowest white blood cell count 
(× 109/l), median (IQR)
2.3 (0.2 to 16.1) 1.9 (0.2 to 6.8) 10.3 (3.1 to 34.6)
Mortality, n (%)
Unit 341 (54.8) 116 (42.7) 126 (40.7)
Acute hospitala 398 (67.3) 141 (55.5) 165 (56.9)
Unit length of stay (days), median 
(IQR)
Unit survivor 2.8 (1.0 to 5.6) 2.2 (1.0 to 4.9) 2.2 (1.0 to 6.1)
Unit nonsurvivor 1.5 (0.6 to 4.4) 3.4 (1.0 to 10.2) 1.5 (0.4 to 6.3)
All 1.9 (0.8 to 5.3) 2.6 (1.0 to 6.7) 1.9 (0.8 to 6.1)
Acute hospital length of stay 
(days)a, median (IQR)
Hospital survivor 38 (27 to 62) 39 (21 to 61) 19 (11 to 41)
Hospital nonsurvivor 15 (3 to 27) 23 (8 to 45) 9 (3 to 24)
All 22 (8 to 39) 29 (13 to 51) 15 (7 to 33)
Readmission within the same acute 
hospital stay, n (%)
28 (4.5) 14 (5.2) 18 (5.8)
Acute hospital mortality by number 
of organ system failures, n (%)
0 organ failures 24 (47.1) 10 (27.8) 16 (29.6)
1 organ failure 99 (54.4) 39 (48.2) 51 (45.5)
2 organ failures 114 (65.9) 49 (60.5) 44 (67.7)
3 organ failures 105 (85.4) 31 (79.5) 38 (90.5)
4 organ failures 47 (88.7) 9 (64.3) 15 (93.8)
5 organ failures 9 (100.0) 3 (100.0) 1 (100.0)
Hodgkin's lymphoma 
(n = 216)
Non-Hodgkin's lymphoma 
(n = 1,007)
Bone marrow transplant 
(n = 156)
Myeloma (n = 397)
Age, mean (SD) 50.7 (17.9) 56.3 (15.8) 40.8 (14.7) 63.0 (11.2)Available online http://ccforum.com/content/13/4/R137
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Male, n (%) 123 (56.9) 611 (60.7) 83 (53.2) 244 (61.5)
APACHE II Acute Physiology 
Score, mean (SD)
16.7 (7.0) 17.2 (7.4) 18.5 (8.6) 17.1 (7.5)
APACHE II score, mean (SD) 23.2 (7.5) 24.1 (8.0) 23.4 (9.5) 24.3 (7.9)
ICNARC physiology score, mean 
(SD)
23.2 (11.0) 24.0 (10.9) 24.0 (12.4) 24.2 (10.8)
Number of organ system failures, 
mean (SD)
1.5 (1.2) 1.5 (1.2) 1.7 (1.3) 1.7 (1.3)
Mechanically ventilated at any time 
during first 24 hours in the ICU, n 
(%)
115 (53.5) 528 (52.7) 69 (45.1) 209 (52.8)
Severe sepsis, n (%) 101 (46.8) 414 (41.1) 68 (43.6) 146 (36.8)
Physiology
Lowest platelet count (× 109/l), 
median (IQR)
75 (29 to 188) 82 (33 to 184) 37 (19 to 62) 95 (47 to 161)
Lowest white blood cell count 
(× 109/l), median (IQR)
6.1 (2.1 to 10.5) 6.3 (1.8 to 13.6) 3.7 (0.6 to 8.2) 4.7 (1.9 to 8.8)
Mortality, n (%)
Unit 119 (55.1) 492 (48.9) 74 (47.4) 151 (38.0)
Acute hospitala 142 (71.0) 625 (66.2) 93 (65.0) 227 (60.1)
Unit length of stay (days), median 
(IQR)
Unit survivor 2.7 (1.2 to 5.4) 2.9 (1.3 to 6.7) 2.6 (1.1 to 8.3) 2.9 (1.2 to 8.1)
Unit nonsurvivor 4.5 (1.2 to 8.7) 2.7 (0.9 to 6.4) 3.9 (1.1 to 7.7) 2.8 (0.7 to 7.4)
All 3.4 (1.2 to 7.2) 2.7 (1.1 to 6.4) 3.0 (1.1 to 7.9) 2.9 (1.1 to 7.7)
Acute hospital length of stay 
(days)a, median (IQR)
Hospital survivor 24 (12 to 44) 29 (15 to 53) 32 (17 to 63) 34 (18 to 55)
Hospital nonsurvivor 15 (6 to 26) 15 (6 to 30) 28 (13 to 46) 14 (5 to 25)
All 17 (8 to 35) 19 (9 to 35) 29 (15 to 54) 20 (9 to 38)
Readmission within the same acute 
hospital stay, n (%)
16 (7.4) 59 (5.9) 11 (7.1) 10 (2.5)
Acute hospital mortality by number 
of organ system failures, n (%)
0 organ failures 26 (54.2) 90 (43.7) 6 (25.0) 24 (32.4)
1 organ failure 43 (71.7) 182 (60.3) 27 (62.8) 54 (49.1)
2 organ failures 38 (70.4) 197 (75.2) 28 (71.8) 70 (68.0)
3 organ failures 24 (88.9) 102 (87.9) 13 (72.2) 41 (77.4)
4 organ failures 10 (100.0) 41 (93.2) 17 (100.0) 27 (100.0)
5 organ failures 1 (100.0) 13 (92.9) 2 (100.0) 11 (100.0)
Only admissions with a haematological diagnosis as the primary, secondary or ultimate reason for admission are included. The numbers with each 
diagnosis are greater than in the logistic regression model because admissions missing hospital outcome and readmissions are excluded from the 
regression analysis. AML: acute myelogenous leukaemia; ALL: acute lymphocytic leukaemia; APACHE: Acute Physiology and Chronic Health 
Evaluation; APS: Acute Physiology Score; CI: confidence interval; CMLL: chronic myelogenous or chronic lymphocytic leukaemia; ICNARC: 
Intensive Care National Audit & Research Centre; ICU: intensive care unit; IQR: interquartile range; SD: standard deviation. aExcluding 
readmissions within the same acute hospital stay.
Table 2 (Continued)
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Effect of organ failure on survival
As the number of organ failures present on admission
increased, there was an increase in hospital mortality (Table
1). If five organ failures were present, the hospital mortality was
98.8%.
Prognostic ability of the SAPS II, APACHE II and ICNARC 
models
The discrimination and calibration of the SAPS II, APACHE II
and ICNARC scores are presented in Table 3. The three mod-
els all showed reasonably good discrimination between survi-
vors and nonsurvivors as assessed by the AUROC (Figure 1),
with the ICNARC model (AUROC = 0.79) demonstrating
slightly better discrimination than the APACHE II and SAPS II
models (AUROC = 0.74).
The APACHE II model gave the best prediction of actual mor-
tality, with an SMR of 1.01. The SAPS II (SMR = 1.13) and
ICNARC models (SMR = 1.25), however, considerably under-
estimated hospital mortality. The calibration of all three mod-
els, as assessed by the Hosmer–Lemeshow goodness-of-fit C
statistic and Cox's calibration regression, was poor. The
APACHE II model was better calibrated than either the SAPS
II model or the ICNARC model. All three models underesti-
mated actual mortality when the predicted mortality was low
(Figure 2), although the APACHE II model lies closer to the
line of perfect fit than the SAPS II model or the ICNARC
model, indicating that it had better calibration than the other
two models when the predicted mortality was low.
Factors associated with acute hospital mortality
The results of multiple logistic regression analysis are summa-
rised in Tables 4 and 5.
Nineteen factors were found to be associated with acute hos-
pital mortality. Patients with severe sepsis had a higher risk of
acute hospital mortality (adjusted odds ratio (OR) = 1.29).
There was also an increase in mortality with increasing age,
with an adjusted OR of 1.14 for every 10-year increase in age.
As the time interval between acute hospital admission and
admission to intensive care increased, the acute hospital mor-
tality also increased. Acute hospital mortality was 54.1% in
patients immediately admitted to the ICU, compared with
70.8% if admission occurred after 20 days or more in hospital.
Other factors found to be associated with an increased risk of
hospital mortality were haematocrit, systolic blood pressure,
respiratory rate, heart rate, GCS, sedation, PaO2:, arterial pH,
urine output, serum sodium, and serum urea. Of these factors,
haematocrit from 20 to 29% (adjusted OR = 4.56), systolic
hypotension <50 mmHg (adjusted OR = 3.66), and a GCS of
3 (adjusted OR = 3.32) conferred the highest odds for hospi-
tal mortality.
Although IMV within 24 hours of ICU admission was not asso-
ciated with hospital mortality after adjustment for other prog-
nostic factors, 70.2% of intubated patients died compared
with 45.3% of nonintubated patients.
Two thousand eight hundred admissions were included in the
subgroup analysis of the effect of diagnosis on outcome.
Admission after HSCT (mortality 65%, adjusted OR = 1.88) or
admission with a diagnosis of Hodgkin's lymphoma (mortality
71%, adjusted OR = 2.38) were both associated with higher
hospital mortality.
Discussion
The acute hospital mortality of patients with haematological
malignancies admitted to adult, general ICUs in England,
Wales and Northern Ireland between 1995 and 2007 was
59.2%. Factors present on admission associated with increas-
ing acute hospital mortality included age, length of hospital
stay prior to admission and the presence of severe sepsis.
Patients with Hodgkin's lymphoma and those who had
received HSCT had an increased risk of death.
We compared the performance of the SAPS II, APACHE II
and ICNARC models in predicting mortality. The ICNARC
model had the best discrimination as assessed by the
AUROC, but significantly underestimates mortality; while the
APACHE II model does not underestimate mortality for this
group of patients, but has slightly less discriminative power
than the ICNARC model. None of the models showed good
calibration as assessed by the Hosmer–Lemeshow goodness-
of-fit test or Cox's calibration regression.
Figure 1
Receiver operating characteristic curves for the SAPS II, APACHE II  and ICNARC physiology scores Receiver operating characteristic curves for the SAPS II, APACHE II 
and ICNARC physiology scores.Available online http://ccforum.com/content/13/4/R137
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Strengths of the study
The present trial is a large study assessing the outcome of
admissions with haematological malignancies to the ICU,
including data from 178 different units. The generalisability of
our results to similar patient populations is enhanced by the
number of units contributing data. The CMPD is recognised to
be of high quality, meaning that the data used in this study are
reliable.
Limitations of the study
The CMPD was not primarily designed to analyse the outcome
of critically ill patients with haematological malignancies,
imposing important limitations on the study. Only routinely col-
lected admission data included in the CMPD were available
for analysis. Therefore, it was not possible to analyse all of the
prognostic factors in haematological malignancy patients,
such as neutropaenia, or the type of HSCT received. We
could not determine whether patients had received allogeneic
or autologous HSCT, or peripheral blood stem cell transplants
prior to ICU admission, where the mortality of patients receiv-
ing these treatments is known to differ. Although we analysed
the effect of leukopaenia on outcome, this is not the same as
neutropaenia. The analysis of the effect of haematological
diagnosis on outcome was also limited by the grouping of dif-
ferent haematological conditions in the past medical history
field of the CMPD. We therefore performed a subgroup anal-
ysis on 2,800 admissions where a precise haematological
diagnosis could be extracted. We are also unable to analyse
Table 3
Model fit – comparison of the SAPS II, APACHE II and ICNARC models
SAPS II model APACHE II model ICNARC model
Eligible admissions, n (%) 4,973 (64.6) 6,212 (80.7) 7,156 (93.1)
Observed deaths 3,030 3,579 4,237
Expected deaths 2,675.2 3,538.5 3,393.3
SMR (95% CI) 1.13 (1.11 to 1.16) 1.01 (0.99–1.03) 1.25 (1.22 to 1.27)
AUROC (95% CI) 0.74 (0.73 to 0.75) 0.74 (0.73 to 0.76) 0.79 (0.78 to 0.80)
Hosmer–Lemeshow Ca statistic
2(10) 568.0 68.0 900.9
P value < 0.001 < 0.001 < 0.001
Cox's calibration regression
Intercept (95% CI) 0.44 (0.38 to 0.51) 0.08 (0.02 to 0.14) 0.62 (0.56 to 0.67)
Slope (95% CI) 0.59 (0.54 to 0.63) 0.80 (0.75 to 0.85) 0.77 (0.73 to 0.81)
2(2) 469.4 54.3 708.95
P value < 0.001 < 0.001 < 0.001
The Hosmer-Lemeshow test divides the data into ten groups and compares the observed mortality in these groups to the predicted mortality given 
by the model. The C statistic is a chi-squared statistic for testing the hypothesis of perfect calibration. A significant value for the C statistic 
indicates that calibration is not perfect.
APACHE II: Acute Physiology and Chronic Health Evaluation II; AUROC: area under the receiver operating characteristic curve; CI: confidence 
interval; ICNARC: Intensive Care National Audit and Research Centre; SAPS II: Simplified Acute Physiology Score II; SMR: standardised mortality 
ratio. a
Figure 2
Calibration plot of SAPS II, APACHE II and ICNARC physiology scores Calibration plot of SAPS II, APACHE II and ICNARC physiology 
scores. A comparison of the goodness-of-fit of the SAPS II, APACHE II 
and ICNARC physiology scores.Critical Care    Vol 13 No 4    Hampshire et al.
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Table 4
Multivariate logistic regression analysis for admissions to critical care units with haematological malignancya
Number of admissions Number of deaths Percentage of deaths Adjusted
Odds ratio (95% CI) P value
Age < 0.001
<45 years 1,512 831 55.0 1.14 (1.09 to 1.20)
45 to 54 years 1,053 622 59.1 Per 10-year increase
55 to 64 years 1,716 1,006 58.6
65 to 74 years 1,852 1,171 63.2
75+ years 1,028 609 59.2
Sex 0.742
Female 2,818 1,709 60.7 1.02 (0.89 to 1.18)
Male 4,343 2,530 58.3 Reference
Diagnostic categoryb < 0.001
Bone marrow transplant 143 93 65.0 1.88 (1.00 to 3.53)
ALL 254 141 55.5 Reference
AML 591 398 67.3 1.37 (0.86 to 2.20)
CLML 290 165 56.9 1.02 (0.58 to 1.80)
Hodgkin's lymphoma 200 142 71.0 2.38 (1.30 to 4.36)
Non-Hodgkin's lymphoma 944 625 66.2 1.46 (0.92 to 2.31)
Myeloma 378 227 60.1 0.79 (0.47 to 1.35)
Highest central temperature 0.100
<36.0°C 127 110 86.6 2.26 (0.97 to 5.29)
36.0 to 38.4°C 3,850 2,205 57.3 Reference
38.5 to 40.9°C 2,900 1,714 59.1 0.94 (0.81 to 1.09)
41.0+°C 121 80 66.1 0.70 (0.41 to 1.20)
Lowest systolic blood pressure < 0.001
<50 mmHg 281 265 94.3 3.66 (1.93 to 6.96)
50 to 59 mmHg 303 251 82.8 1.66 (1.09 to 2.54)
60 to 69 mmHg 601 472 78.5 1.55 (1.15 to 2.08)
70 to 79 mmHg 1,005 667 66.4 1.10 (0.88 to 1.37)
80 to 99 mmHg 2,598 1,493 57.5 1.14 (0.97 to 1.34)
100+ mmHg 2,270 1,018 44.9 Reference
Highest heart rate < 0.001
<110 beats/min 1,895 788 41.6 Reference
110 to 119 beats/min 1,031 553 53.6 1.32 (1.06 to 1.64)
120 to 139 beats/min 2,119 1,326 62.6 1.57 (1.30 to 1.90)
140+ beats/min 2,019 1,503 74.4 2.07 (1.67 to 2.55)
Highest respiratory rate, ventilated or 
nonventilated
< 0.001
<6 breaths/min 217 141 65.0 1.03 (0.69 to 1.53)
6 to 11 breaths/min 1,840 893 48.5 ReferenceAvailable online http://ccforum.com/content/13/4/R137
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the effect of physiology on outcome beyond the first 24 hours
of ICU stay, where deteriorating physiology may be useful in
making decisions regarding withholding or withdrawing treat-
ment. We are not able to report on long-term follow up for mor-
tality in these admissions.
It is likely that this retrospective study was subject to inclusion
bias. Differences in admission policies among the contributing
units may have led to the inclusion of data from patients with
incurable illness who were certain to die, and to the exclusion
of critically ill patients with haematological malignancy who
were managed on the ward, of whom there are a large number
[6]. Eligible patients may have been omitted, or ineligible
patients included. For example, HSCT may be used to treat
some solid tumours and autoimmune disorders, as well as hae-
matological malignancies. The proportion of HSCT patients,
however, was small (143 out of 7,689 admissions) – the
majority of whom would have had a haematological
malignancy.
During the time period covered by the present study, several
novel therapies for critically ill haematological malignancy
patients have been introduced, such as noninvasive ventilation
and recombinant colony-stimulating factors. The use of these
therapies may have improved the survival of many patients
included in this study [29]. In addition, the management of
sepsis has been improved by the introduction of the Surviving
Sepsis Campaign in 2002. It has been suggested that cancer
patients with severe sepsis have a better chance of survival
than in the past [30,31]. Despite this, the unit and hospital
mortality rates of patients in this study did not change signifi-
cantly over time (data not shown). Finally, lead-time bias may
have affected the results. Lead-time bias results from patients'
12 to 13 breaths/min 1,623 1,039 64.0 1.36 (1.12 to 1.65)
14 to 24 breaths/min 2,899 1,743 60.1 1.57 (1.31 to 1.87)
25+ breaths/min 468 344 73.5 2.81 (2.00 to 3.95)
PaO2:FiO2 < 0.001
Ventilated
<100 mmHg 580 386 66.6 2.78 (2.11 to 3.66)
100 to 199 mmHg 888 446 50.2 1.34 (1.07 to 1.69)
200+ mmHg 1,162 441 38.0 Reference
Nonventilated
<100 mmHg 1,220 1,033 84.7 2.71 (1.45 to 5.06)
100 to 199 mmHg 1,374 951 69.2 1.33 (0.72 to 2.45)
200+ mmHg 1,108 621 56.1 1.06 (0.58 to 1.95)
Lowest arterial pH < 0.001
<7.15 1,248 1,125 90.1 2.25 (1.71 to 2.96)
7.15 to 7.24 1,129 817 72.4 1.37 (1.11 to 1.70)
7.25 to 7.32 1,457 797 54.7 1.09 (0.91 to 1.30)
7.33 to 7.49 2,453 1,094 44.6 Reference
7.50+ 93 61 65.6 2.20 (1.24 to 3.92)
Serum sodium <0.001
<130 mmol/l 285 208 73.0 2.47 (1.70 to 3.60)
130 to 149 mmol/l 6,125 3,486 56.9 Reference
150 to 154 mmol/l 248 196 79.0 1.85 (1.25 to 2.73)
155 to 159 mmol/l 72 63 87.5 3.28 (1.45 to 7.40)
160+ mmol/l 36 28 77.8 1.34 (0.52 to 3.46)
aAnalysis of the effect of age, gender, diagnostic category, temperature, systolic blood pressure, heart rate, respiratory rate, PaO2:FiO2, arterial pH 
and serum sodium on outcome. ALL: acute lymphoblastic leukaemia; AML: acute myeloblastic leukaemia; CI: confidence interval; CLML: chronic 
lymphocytic or myeloblastic leukaemia. bOnly admissions with a haematological diagnosis as the primary, secondary or ultimate reason for 
admission were included in this analysis.
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Table 5
Multivariate logistic regression analysis for admissions to critical care units with haematological malignancya
Number of admissions Number of deaths Percentage of deaths Adjusted
Odds ratio (95% CI) P value
Serum potassium
<3.0 mmol/l 63 45 71.4 2.40 (1.02 to 5.67) 0.226
3.0 to 3.4 mmol/l 274 169 61.7 1.29 (0.87 to 1.92)
3.5 to 5.4 mmol/l 5,548 3,124 56.3 Reference
5.5 to 5.9 mmol/l 431 303 70.3 0.93 (0.69 to 1.27)
6.0 to 6.9 mmol/l 343 260 75.8 1.12 (0.79 to 1.61)
7.0+ mmol/l 106 83 78.3 0.79 (0.40 to 1.53)
Serum urea <0.001
<6.2 mmol/l 1,315 504 38.3 1.05 (0.78 to 1.42)
6.2 to 7.1 mmol/l 422 189 44.8 Reference
7.2 to 14.3 mmol/l 2,158 1,272 58.9 1.45 (1.09 to 1.93)
14.4+ mmol/l 2,283 1,666 73.0 2.39 (1.74 to 3.28)
Serum creatinine 0.310
<0.6 mol/l 193 94 48.7 1.41 (0.94 to 2.13)
0.6 to 1.4 mol/l 3,104 1,510 48.7 Reference
1.5+ mol/l 3,359 2,302 68.5 0.84 (0.70 to 1.02)
Urine output < 0.001
<400 ml/day 1,121 956 85.3 2.91 (2.23 to 3.79)
400 to 599 ml/day 297 239 80.5 2.66 (1.76 to 4.00)
600 to 899 ml/day 488 341 69.9 2.05 (1.53 to 2.75)
900 to 1,499 ml/day 1,270 752 59.2 1.58 (1.30 to 1.91)
1,500 to 1,999 ml/day 984 515 52.3 1.37 (1.13 to 1.66)
2,000+ ml/day 2,689 1,229 45.7 Reference
Haematocrit 0.001
<20% 171 119 69.9 3.22 (0.96 to 10.85)
20 to 29% 3,073 1,904 62.0 4.56 (1.51 to 13.80)
30 to 45% 3,405 1,897 55.7 3.69 (1.22 to 11.13)
46 to 49% 55 28 50.9 2.13 (0.58 to 7.82)
50 to 59% 26 10 38.5 Reference
60+% 5 3 60.0 1.24 (0.09 to 17.20)
Lowest white blood cell count 0.425
<1 × 109/l 1,217 799 65.7 1.17 (00.95 to 1.45)
1 to 2 × 109/l 820 503 61.3 1.15 (0.92 to 1.43)
3 to 14 × 109/l 3,009 1,605 53.3 Reference
15 to 39 × 109/l 1,039 616 59.3 0.98 (0.80 to 1.20)
40+ × 109/l 459 301 65.6 1.16 (0.86 to 1.56)
Glasgow Coma Score < 0.001Available online http://ccforum.com/content/13/4/R137
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physiology improving as they receive therapy usually provided
in the ICU while awaiting ICU admission.
Predictive power of the APACHE II, SAPS II and ICNARC 
models
The SAPS II and APACHE II models have been assessed in
small studies of critically ill haematological malignancy
patients. The AUROC for SAPS II was found to be 0.765 [32]
and 0.78 [12]. Benoit and colleagues found that the SAPS II
model had better discrimination than the APACHE II model
(AUROC = 0.712) [32]; however, both studies included only
small numbers of patients. Both the ICNARC and SAPS II
models underestimated actual mortality in this study. Underes-
timation of mortality in haematological malignancy patients by
the SAPS II model has been previously described [6,11]. The
APACHE II model has also been found to underestimate mor-
tality in these patients [8,11], but we found that the APACHE
II model gave the most accurate mortality prediction (Table 3)
with an SMR of 1.01.
Effect of organ failure on survival
As the number of organ failures present on admission
increased, the hospital mortality also increased; less than 10%
of patients with four organ failures survived, and hospital mor-
tality was 98.8% when there were five organ failures present
on admission (Tables 1 and 2).
Risk factors for hospital mortality
Previous studies have identified risk factors for hospital mortal-
ity following admission to the ICU with a haematological malig-
nancy (Table 6). We were able to assess the effects of
haematological diagnosis, HSCT, hospital length of stay, age,
3 511 437 85.5 3.32 (2.33 to 4.74)
4 29 21 72.4 1.58 (0.55 to 4.52)
5 30 22 73.3 2.20 (0.85 to 5.73)
6 81 54 66.7 1.47 (0.80 to 2.71)
7 to 13 595 392 65.9 1.80 (1.40 to 2.31)
14 376 223 59.3 1.48 (1.11 to 1.98)
15 3,190 1,385 43.4 Reference
Sedated 1,518 1,119 73.7 1.85 (1.50 to 2.28)
Sedated and paralysed 214 173 80.8 2.40 (1.51 to 3.82)
Mechanical ventilation 0.154
No 3,169 1,435 45.3 Reference
Yes 3,970 2,788 70.2 1.53 (0.85 to 2.73)
Severe sepsis 0.001
No 3,245 1,630 50.2 Reference
Yes 3,916 2,609 66.6 1.29 (1.10 to 1.50)
CPR within 24 hours prior to admission 0.317
No 6,728 3,884 57.7 Reference
Yes 426 353 82.9 1.21 (0.84 to 1.74)
Hospital length of stay before ICU 
admission
< 0.001
0 days 1,358 735 54.1 1.02 (1.01 to 1.02)
1 day 1,266 614 48.5 (per day)
2 to 4 days 1,253 690 55.1
5 to 9 days 977 617 63.2
10 to 19 days 1,109 735 66.3
>20 days 1,195 846 70.8
aAnalysis of the effect of serum potassium, urea, creatinine, urine output, haematocrit, white cell count, Glasgow Coma Score, invasive ventilation, 
severe sepsis, cardiopulmonary resuscitation (CPR) and length of hospital stay prior to intensive care admission on outcome. CI: confidence 
interval; ICU: intensive care unit.
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admission physiology, IMV, and severe sepsis within the first
24 hours of admission.
Haematological diagnosis
We found that patients diagnosed with Hodgkin's lymphoma
had an increased risk of hospital mortality (adjusted OR =
2.38). This is an unexpected finding, since patients with Hodg-
kin's lymphoma have a relatively good long-term prognosis.
Groeger and colleagues found in cancer patients receiving
IMV that those with leukaemia had a higher mortality [33]. Mas-
sion and colleagues found that acute myeloid leukaemia and
non-Hodgkin's lymphoma had a negative effect on 6-month
survival [11]. In the present study, patients with acute myeloid
leukaemia had a higher mortality than those with acute lym-
phocytic leukaemia, perhaps partially explained by the differ-
ence in mean age between these admissions (Table 2).
Patients with chronic lymphocytic leukaemia had the best
prognosis in the study by Peters and colleagues [7]. Other
researchers, however, have found that the type of haematolog-
ical malignancy was not predictive for mortality [13,16].
Bone marrow transplant
Admission after bone marrow transplantation (HSCT) was a
risk factor for acute hospital mortality in the present study. The
hospital mortality in patients who become critically ill after
HSCT is 54 to 67% [1,34,35], with higher mortality rates
reported in intubated patients [3,16,36,37]. Patients who
receive autologous HSCT transplants undergo less intensive
preparative regimens and faster marrow engraftment, so a
lower mortality would be expected. Khassawneh and col-
leagues found that the hospital mortality rate in such patients
who were intubated was 74% [38]. Indeed, allogeneic HSCT
has been identified as a risk factor for mortality [33,34]. Other
studies, however, have found that the type of HSCT has no
influence on mortality [3,35,39]. Dividing HSCT patients into
those receiving autologous and allogeneic transplants is not
possible in the present study, as the type of HSCT received is
not recorded in the CMPD.
Admission physiology
Tachypnoea, a low PaO2:FiO2 and hypotension were associ-
ated with increased hospital mortality. The relationship
between respiratory failure and increased risk of mortality has
already been demonstrated [11]. Requirement for vasopres-
sors has also been associated with a worse outcome in these
patients [12,32,39].
In the present study oliguria, hyponatraemia and uraemia cor-
related with mortality. These abnormalities may result from
acute kidney injury, which is strongly associated with mortality
in haematological malignancy patients [14,32].
Arterial pH
Acidaemia was associated with lower survival. Acute kidney
injury or high serum lactate may cause acidosis, and both con-
ditions predicted higher mortality in previous studies
[1,14,32,40,41].
Table 6
Risk factors for mortality in patients admitted to intensive care with haematological malignancy
Study Factors identified that are associated with hospital mortality
Owzcuk and colleagues [16] High SAPS II, SOFA score or APACHE II score, neutropaenia, hypotension, cardiovascular failure
Yau and colleagues [9] Progression of underlying malignancy
Massion and colleagues [11] Respiratory failure, fungal infection, number of organ failures, haemopoeitic stem cell transplant status
Benoit and colleagues [32] Leukopaenia, use of vasopressors, urea >0.75 g/l
Gordon and colleagues [6] Hepatic failure, central nervous system failure, SAPS II score >66
Lim and colleagues [39] Raised bilirubin, inotropic support, more than three organ failures
Lloyd-Thomas and colleagues [8] High APACHE II score, number of organ failures, mechanical ventilation
Brunet and colleagues [10] SAPS II score, more than one organ failure
Kroschinsky and colleagues [14] Haemofiltration, high SAPS II score
Silfvast and colleagues [50] Maximal SOFA score on admission
Cornet and colleagues [17] SAPS II and SOFA score over 96 hours
Lamia and colleagues [12] Severe sepsis or septic shock, vasopressor use, invasive ventilation, neutropaenia, allogeneic haemopoeitic 
stem cell transplant, high SAPS II, SOFA score, ODIN score or LODS score
Bianchi and colleagues [41] Mechanical ventilation, neutropaenia, renal failure
APACHE II: Acute Physiology and Chronic Health Evaluation II; LODS: Logistic Organ Dysfunction Score; ODIN: Organ Dysfunction and/or 
Infection score; SAPS II: Simplified Acute Physiology Score II; SOFA: Sequential Organ Failure Assessment.Available online http://ccforum.com/content/13/4/R137
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Invasive mechanical ventilation
Most studies report a strong relationship between IMV and
increased mortality [8,12,41]. Using noninvasive ventilation
rather than IMV reduces mortality in immunocompromised
patients [42,43]. IMV during the first 24 hours of admission
was not associated with an increased risk of mortality in this
study, although a large absolute difference in mortality exists
between patients who received IMV and those who did not.
Depudyt and colleagues found that IMV within 24 hours of ICU
admission was related to a lower mortality rate in haematolog-
ical malignancy patients with respiratory failure [44]. Consid-
ering those patients who had PaO2:FiO2 lower than 200
mmHg in the present study, a similar conclusion may be
drawn, as those who were invasively ventilated within 24 hours
had lower mortality rates than those who were not. Indeed, we
found that severe respiratory failure (PaO2:FiO2 < 100 mmHg)
without IMV is associated with increased hospital mortality.
This may reflect reluctance to use IMV in such patients, as less
than one-third of patients who had a PaO2:FiO2 < 100 mmHg
received IMV (Table 5).
Leukopaenia
We did not find an association between leukopaenia and mor-
tality, although in previous studies leukopaenia was identified
as a significant risk factor [8,32] and leukopaenia is a compo-
nent of the APACHE II score and the SAPS II. We were unable
to assess the effect of neutropaenia on mortality, as this is not
a recorded parameter in the CMPD.
Glasgow Coma Score
A low GCS was independently associated with mortality. Gor-
don and colleagues [6] found that central nervous system fail-
ure was associated with higher mortality.
The retrospective nature of the present study should lead to
caution in interpreting the factors identified as being associ-
ated with mortality. Severe sepsis – together with cardiorespi-
ratory and renal dysfunction – was associated with increased
mortality, however, and this implies that early, aggressive treat-
ment aimed at reversing organ dysfunction may improve sur-
vival, particularly in those patients with severe sepsis.
We also found that acute hospital mortality was associated
with a longer stay in hospital prior to ICU admission. This is
probably due to delayed recognition and suboptimal treatment
of patients who have become acutely unwell on the ward, sug-
gesting that earlier admission to the ICU may benefit some
patients. Groeger and colleagues found a correlation between
hospital length of stay prior to ICU admission and mortality in
critically ill cancer patients [33,45,46], and this has also been
found in critically ill patients as a whole [47].
A low haematocrit of between 20% and 45% was associated
with higher mortality, compared with admissions with a haema-
tocrit of between 50% and 59. Anaemia has not previously
been associated with an increased risk of hospital mortality in
critically ill patients with haematological malignancy. Current
practice in intensive care patients is to tolerate a fall in haema-
tocrit, excepting certain groups of patients, based on evidence
that this practice is not harmful [48]. On the other hand, in the
early phase of severe sepsis, targeting a haematocrit of at
least 30% is associated with improved survival [49]. In
patients with a haematological malignancy a low haematocrit
is common, and its causes are multifactorial. The low haemat-
ocrit may be chronic (resulting from bone marrow suppression
or more aggressive chemotherapy) or acute (secondary to
haemorrhage). One interpretation of our results would suggest
that if haematology malignancy patients were managed with a
higher haematocrit, at least initially, then their mortality may be
reduced.
The association between hospital mortality and sedation may
be partially explained by confounding with the adverse effect
on mortality of mechanical ventilation. The relationship
between hospital mortality and anaemia on admission in these
patients is surprising given previous evidence of safety in tol-
erating a low haematocrit in intensive care patients. Further
studies should be conducted to refute or confirm this
relationship.
Conclusions
The ICU mortality for haematological malignancy patients in
this study was 43.1% and the hospital mortality was 59.2%.
Admission factors associated with an increased risk of death
were severe sepsis, age, bone marrow transplant, Hodgkin's
lymphoma, length of hospital stay prior to intensive care admis-
sion, tachycardia, systolic blood pressure <70 mmHg, tachyp-
noea, GCS, sedation, PaO2:FiO2, acidaemia, alkalaemia,
oliguria, hyponatraemia, hypernatraemia, low haematocrit, and
uraemia. In contrast to previous studies, we did not find that
leukopaenia was associated with increased hospital mortality.
We did, however, find that a low haematocrit was associated
with higher hospital mortality. This finding warrants further
investigation in a prospective study.
The ICNARC model had the best discrimination of the three
scores analysed, with an AUROC of 0.78, but all scores were
poorly calibrated. The APACHE II model had the highest accu-
racy at predicting hospital mortality, with a SMR of 1.01. The
SAPS II and the ICNARC score both underestimated hospital
mortality.
Increased hospital mortality is associated with both increasing
length of hospital stay prior to ICU admission and severe sep-
sis, suggesting that, if appropriate, such patients should be
admitted to the ICU early and treated aggressively.
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